[
  {
    "ts": null,
    "headline": "Eli Lilly and Company (LLY) Needs To Get A Weight Loss Pill Out, Says Jim Cramer",
    "summary": "We recently published 12 Stocks Jim Cramer Discussed As He Said SpaceX’s Starlink Internet Could Help President Trump. Eli Lilly and Company (NYSE:LLY) is one of the stocks Jim Cramer recently discussed. Eli Lilly and Company (NYSE:LLY)’s shares have become one of the most valuable in the sector due to its strong presence in the […]",
    "url": "https://finnhub.io/api/news?id=f9a91c4c5b194b689b38beadc3e8a586bdabf9bfae185b24c0627e282c8135f1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756500611,
      "headline": "Eli Lilly and Company (LLY) Needs To Get A Weight Loss Pill Out, Says Jim Cramer",
      "id": 136579594,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "We recently published 12 Stocks Jim Cramer Discussed As He Said SpaceX’s Starlink Internet Could Help President Trump. Eli Lilly and Company (NYSE:LLY) is one of the stocks Jim Cramer recently discussed. Eli Lilly and Company (NYSE:LLY)’s shares have become one of the most valuable in the sector due to its strong presence in the […]",
      "url": "https://finnhub.io/api/news?id=f9a91c4c5b194b689b38beadc3e8a586bdabf9bfae185b24c0627e282c8135f1"
    }
  },
  {
    "ts": null,
    "headline": "Mounjaro Price Bomb Sparks UK Pharmacy Rebellion--Wegovy Cashes In",
    "summary": "Eli Lilly's obesity drug price surge ignites chaos, stockouts, and a golden opening for rival Novo Nordisk.",
    "url": "https://finnhub.io/api/news?id=c41a860256be3e6fa7f0bb268da3224cbb983211456db058647185aa46c6be60",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756494368,
      "headline": "Mounjaro Price Bomb Sparks UK Pharmacy Rebellion--Wegovy Cashes In",
      "id": 136575311,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly's obesity drug price surge ignites chaos, stockouts, and a golden opening for rival Novo Nordisk.",
      "url": "https://finnhub.io/api/news?id=c41a860256be3e6fa7f0bb268da3224cbb983211456db058647185aa46c6be60"
    }
  },
  {
    "ts": null,
    "headline": "Jim Cramer Sees Big Potential in Eli Lilly’s Weight-Loss and Diabetes Pill",
    "summary": "Eli Lilly and Company (NYSE:LLY) is one of the stocks that Jim Cramer shared insight on. A caller inquired about the company, noting its recent approval for a memory loss treatment. Cramer replied: “Okay, the memory loss is not that important… because it’s just a very hard thing. I mean, actually, if you want memory […]",
    "url": "https://finnhub.io/api/news?id=8996602a6da8d5d17214f8591fecc2e08417f4da0706b9a5dd7547d11db82a8c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756494330,
      "headline": "Jim Cramer Sees Big Potential in Eli Lilly’s Weight-Loss and Diabetes Pill",
      "id": 136575312,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE:LLY) is one of the stocks that Jim Cramer shared insight on. A caller inquired about the company, noting its recent approval for a memory loss treatment. Cramer replied: “Okay, the memory loss is not that important… because it’s just a very hard thing. I mean, actually, if you want memory […]",
      "url": "https://finnhub.io/api/news?id=8996602a6da8d5d17214f8591fecc2e08417f4da0706b9a5dd7547d11db82a8c"
    }
  },
  {
    "ts": null,
    "headline": "Sector Update: Health Care Stocks Advance Friday Afternoon",
    "summary": "Health care stocks rose Friday afternoon, with the NYSE Health Care Index and the Health Care Select",
    "url": "https://finnhub.io/api/news?id=1e27cf71122ff0355b1d326a087b9d3b9c6da0420bf6c4f8dba99d6e951bd22f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756489026,
      "headline": "Sector Update: Health Care Stocks Advance Friday Afternoon",
      "id": 136574838,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Health care stocks rose Friday afternoon, with the NYSE Health Care Index and the Health Care Select",
      "url": "https://finnhub.io/api/news?id=1e27cf71122ff0355b1d326a087b9d3b9c6da0420bf6c4f8dba99d6e951bd22f"
    }
  },
  {
    "ts": null,
    "headline": "The Zacks Analyst Blog Highlights Lilly, Oracle, Procter & Gamble and Comstock Holding Companies",
    "summary": "Zacks spotlights Eli Lilly, Oracle, Procter & Gamble, and microcap Comstock Holding, with pharma and staples facing pressure while Oracle and Comstock show momentum.",
    "url": "https://finnhub.io/api/news?id=688f773711d3d6ef4241241395a723c65fa9d759601f0dd51563e08e101a8f7c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756486680,
      "headline": "The Zacks Analyst Blog Highlights Lilly, Oracle, Procter & Gamble and Comstock Holding Companies",
      "id": 136575314,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Zacks spotlights Eli Lilly, Oracle, Procter & Gamble, and microcap Comstock Holding, with pharma and staples facing pressure while Oracle and Comstock show momentum.",
      "url": "https://finnhub.io/api/news?id=688f773711d3d6ef4241241395a723c65fa9d759601f0dd51563e08e101a8f7c"
    }
  },
  {
    "ts": null,
    "headline": "Teva brings first generic GLP-1 to US market with Saxenda copycat approval",
    "summary": "Although Saxenda is the first generic GLP-1 to hit the US market, its sales will likely be overshadowed by next-gen drugs such as Wegovy and Zepbound.",
    "url": "https://finnhub.io/api/news?id=aa5cee06652493c713b6f299c813ca06eb2a878181f2194ed58c3e2d7236825e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756484125,
      "headline": "Teva brings first generic GLP-1 to US market with Saxenda copycat approval",
      "id": 136573039,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Although Saxenda is the first generic GLP-1 to hit the US market, its sales will likely be overshadowed by next-gen drugs such as Wegovy and Zepbound.",
      "url": "https://finnhub.io/api/news?id=aa5cee06652493c713b6f299c813ca06eb2a878181f2194ed58c3e2d7236825e"
    }
  },
  {
    "ts": null,
    "headline": "ABBV or MRK: Which Stock Should Investors Place Their Bet on in 2025?",
    "summary": "AbbVie edges past Merck in 2025 as strong Skyrizi and Rinvoq sales, pipeline gains and rising estimates fuel growth momentum.",
    "url": "https://finnhub.io/api/news?id=5778f05411a82196571c26c33b1c12ac8249bff2e5939836b87b49deb3fee059",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756477020,
      "headline": "ABBV or MRK: Which Stock Should Investors Place Their Bet on in 2025?",
      "id": 136573040,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "AbbVie edges past Merck in 2025 as strong Skyrizi and Rinvoq sales, pipeline gains and rising estimates fuel growth momentum.",
      "url": "https://finnhub.io/api/news?id=5778f05411a82196571c26c33b1c12ac8249bff2e5939836b87b49deb3fee059"
    }
  },
  {
    "ts": null,
    "headline": "BofA update shows where active managers are putting money",
    "summary": "Investing.com -- Active managers rotated back into technology and industrials in the last quarter, while shedding health care exposure, according to a new update from Bank of America.",
    "url": "https://finnhub.io/api/news?id=c6b7c927995db0d134e5e0aba674663a789a8010a56e033c9e33b94cd7161cd8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756471467,
      "headline": "BofA update shows where active managers are putting money",
      "id": 136568817,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Investing.com -- Active managers rotated back into technology and industrials in the last quarter, while shedding health care exposure, according to a new update from Bank of America.",
      "url": "https://finnhub.io/api/news?id=c6b7c927995db0d134e5e0aba674663a789a8010a56e033c9e33b94cd7161cd8"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Smashes Earnings, Bets Big On Depression Drug Bretisilocin",
    "summary": "AbbVie's strong financial results for the second quarter of 2025 were ensured by its two superstars, Rinvoq and Skyrizi. Click here to read my latest analysis.",
    "url": "https://finnhub.io/api/news?id=cd5b0e7f7073f7c6b99befc729473d98b794028f55711773ec7140c00fc76cbf",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756471054,
      "headline": "AbbVie Smashes Earnings, Bets Big On Depression Drug Bretisilocin",
      "id": 136571810,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1823932204/image_1823932204.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "AbbVie's strong financial results for the second quarter of 2025 were ensured by its two superstars, Rinvoq and Skyrizi. Click here to read my latest analysis.",
      "url": "https://finnhub.io/api/news?id=cd5b0e7f7073f7c6b99befc729473d98b794028f55711773ec7140c00fc76cbf"
    }
  },
  {
    "ts": null,
    "headline": "Cost of Mounjaro to be discounted in UK pharmacies",
    "summary": "It comes after an announcement from Eli Lilly that the UK list price for the drug is set to rise from September 1.",
    "url": "https://finnhub.io/api/news?id=69fbf9f43bd5892f5e983fd4c4f18c9eb4a7fb8f7275d0dd779d0ef0414d2be7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756468763,
      "headline": "Cost of Mounjaro to be discounted in UK pharmacies",
      "id": 136569042,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "It comes after an announcement from Eli Lilly that the UK list price for the drug is set to rise from September 1.",
      "url": "https://finnhub.io/api/news?id=69fbf9f43bd5892f5e983fd4c4f18c9eb4a7fb8f7275d0dd779d0ef0414d2be7"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Stock: Is LLY Underperforming the Healthcare Sector?",
    "summary": "Although Eli Lilly has trailed the broader healthcare sector over the past year, analysts maintain a strongly bullish outlook on the stock’s long-term growth potential.",
    "url": "https://finnhub.io/api/news?id=db00b9a34b92efcdbc388ef337b285a52e35f0c8683c500224d103081180a6d3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756465866,
      "headline": "Eli Lilly Stock: Is LLY Underperforming the Healthcare Sector?",
      "id": 136569045,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Although Eli Lilly has trailed the broader healthcare sector over the past year, analysts maintain a strongly bullish outlook on the stock’s long-term growth potential.",
      "url": "https://finnhub.io/api/news?id=db00b9a34b92efcdbc388ef337b285a52e35f0c8683c500224d103081180a6d3"
    }
  }
]